OREANDA-NEWS.  February 14, 2014. Protek (Bloomberg: PRTK:RU), one of the largest Russian pharmaceutical companies, encompassing the distribution, retail and production segments, reported preliminary 12M13 consolidated figures in terms of revenue. 4Q13 numbers were inline with trends which were seen in the company’s performance in 2013.

Protek saw a decrease in its core segment – distribution (0.5% down y-o-y), which was offset by solid growth rates in two other segments - retail and production, with corresponding increase of 17% and 30% y-o-y in the quarter.

In 4Q13, the company continued to see a strong competitive activity in the distribution segment. As a result, Protek saw a moderate 2% y-o-y growth in consolidated revenue in 4Q13, while the FY13 result (11% up y-o-y) looks healthy.